The PTC-CTP grant from the Alzheimer's Association funds biomarker-driven clinical trials testing combination therapies for Alzheimer’s disease and related dementias.
Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.
The Tau Pipeline Enabling Program V funds translational research to develop and advance therapies targeting tauopathies, led by the Alzheimer's Association.
Accelerating Drug Discovery for FTD supports investigators developing small molecule and biologic drugs through lead optimization and animal-model testing to advance disease-modifying treatments for FTD.
This grant supports academic and biotech researchers in developing new drugs to prevent, slow, or treat Alzheimer’s disease through preclinical and early-stage clinical research.